Apricus Biosciences to Present at Three Upcoming Investor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014

SAN DIEGO, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members of senior management will present at the following three investor conferences, each of which will be webcast live and for replay at http://www.apricusbio.com/investor-relations/presentations/ .

SeeThruEquity Microcap Investor Conference
Wednesday, November 12, 2014
Presentation at 9:30 a.m. ET
Convene Midtown East, New York, NY
Online Registration
 
Stifel 2014 Healthcare Conference
Tuesday, November 18, 2014
Presentation at 4:45 p.m. ET
The New York Palace Hotel, New York, NY
 
LD Micro Conference
Thursday, December 4, 2014
Presentation at 11:00 a.m. PT
Luxe Hotel, Los Angeles, CA

Management will review its plans for growth to include discussing its robust pipeline of marketed and development stage products:

  • Vitaros ® , the Company's topical treatment for erectile dysfunction which launched in Belgium this week and in the United Kingdom, Germany and Sweden earlier this year;
  • Fispemifene , Apricus' newly in-licensed drug candidate for male urological conditions including low testosterone "Low T" also known as secondary hypogonadism, is slated for a phase 2b trial to commence in the first half of 2015;
  • RayVa ™ , a potential first-in-class drug candidate for the circulatory disorder, Raynaud's phenomenon, which will commence a ~50 patient phase 2a proof of concept trial in Q4 of this year.

About Apricus Biosciences, Inc .

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines to meet the needs of patients. The Company's lead product, Vitaros ® , for the treatment of erectile dysfunction, is approved in Europe and Canada and commercialized in several countries in Europe. Apricus' marketing partners for Vitaros ® include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros room temperature device is under development and is expected to enhance the product's commercial value. The Company recently initiated a Phase 2a trial for RayVa™, the Company's product candidate for the treatment of Raynaud's phenomenon. Femprox ® , the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox. In October 2014, Apricus gained U.S. development and commercialization rights for fispemifene, a selective estrogen receptor modulator, in Phase 2 development.

For further information on Apricus, visit http://www.apricusbio.com .

Steve Martin Apricus Biosciences Chief Financial Officer (858) 222-8041 Institutional Investors: Angeli Kolhatkar Media: Justin Jackson Burns McClellan (212) 213-0006 Retail Investors: Chris Eddy, David Collins Catalyst Global (212) 924-9800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 22

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 20

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 0

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 60

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 78

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 204

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 0

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 27

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AML's Innovative Permanent Magnet Manufacturing

Updated Category News Views 246

Revolutionizing Permanent Magnet Production Advanced Magnet Lab, Inc. (AML) has emerged as a frontrunner in the field of innovative magnet technologies. By harnessing their advanced PM-Wire™ manufacturing process, AML is setting the stage for a broad range of applications that require permanent magnets. This new technology opens avenues for diverse supply chain...

Continue Reading
Harmonic Secures $75 Million Funding to Innovate AI Mathematics

Updated Category News Views 475

Harmonic Secures $75 Million in Series A Funding Harmonic, a Palo Alto-based innovator in artificial intelligence, has just revealed that it successfully raised $75 million in a Series A funding round. This investment values the company at $325 million, led by the well-known venture capital firm Sequoia Capital, alongside significant backing from Index Ventures and...

Continue Reading
Peoria's Mercedes-Benz of Arrowhead Offers Luxury 3-Row SUVs

Updated Category News Views 22

Luxury SUVs with Space and Sophistication When it comes to racking up the mileage in style, finding that sweet spot between luxury and practicality is the holy grail for many car buyers. Right in the heart of Peoria, Arizona, Mercedes-Benz of Arrowhead is rolling out a red carpet for those of us who crave both opulence and utility in one sleek package. Why Third-Row...

Continue Reading
Understanding the Rise in Comfort Systems USA's Short Interest

Updated Category News Views 176

Understanding Comfort Systems USA's Short Interest The short interest of Comfort Systems USA (NYSE: FIX) has seen a notable rise, increasing by 40.65% since the last report. This reflects growing concerns or speculation surrounding the company's stock performance. Currently, approximately 536 thousand shares are sold short, which constitutes 2.18% of the total shares...

Continue Reading
Investigating Today's Top 5 Stocks: Trends and Insights

Updated Category News Views 181

Market Overview Stocks in the U.S. presented a mixed picture recently, with notable fluctuations in the major indexes. The Dow Jones Industrial Average saw a slight dip of 0.1%, closing at 44,837.56, while the S&P 500 remained stable at 6,389.77. Meanwhile, the Nasdaq climbed slightly, gaining 0.3% to end the day at 21,178.58. Top Five Stocks to Watch Today Market...

Continue Reading